Late-stage N-Me selective alkenylation and alkynylation of drugs and unactivated tertiary amines using photoredox catalysis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41680185.
- Also identified by DOI 10.1038/s41467-026-69131-7 and PMC identifier 13009150.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Late-stage functionalization (LSF) of marketed drugs facilitates novel chemical space around drug leads. Considering alkyl tertiary amines are present in a large number of life-saving drugs, the development of a LSF strategy to introduce functionalizable groups provides a toolbox for future drug discovery. The introduction of vinyl and alkyne groups into a marketed drug also offers numerous advantages and potential applications, including augmented structural diversity, bio-orthogonal labeling, click chemistry, pharmacological modulation, and drug conjugation strategies. Herein, we report a synthetic strategy for N-methyl selective alkenylation and alkynylation of aliphatic tertiary amines using organophotoredox catalysis and their application to the late-stage functionalization of marketed drugs. Molecular modeling followed by bioactivity studies of novel imipramine alkenylated and alkynylated analogues shows improved efficiency compared to imipramine in reducing the depressive state, justifying the importance of N-methyl selective alkenylation and alkynylation. A thorough investigation of the reaction mechanism has been conducted to understand the regioselective formation of the N-Me selective product. DFT calculations combined with experimental evidence indicate that the regioselective outcome is controlled by the radical addition step not the radical formation step, which mostly remains unknown.
Medical subject headings
- Alkynes
- Amines